Physician profile
Judith E Strapp
NPI 1770693228
$3,002.24
in general payments reported to CMS, 2019-2025
25 companies · $973 in 2025
The $973 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $228 · 2022: $98.57 · 2023: $425 · 2024: $1,278 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,676.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $376.36 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $278.87 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $260.38 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $254.50 | 2021-2024 | |
| Dexcom, INC. | $193.58 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $185.92 | 2023-2025 | Zoryve, Livalo |
| Novo Nordisk INC | $184.65 | 2024-2025 | Wegovy, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $161.99 | 2023-2025 | Xifaxan, Trulance |
| Exact Sciences Corporation | $145.72 | 2023-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $143.74 | 2025 | Voquezna |
| Inspire Medical Systems, INC. | $111.31 | 2024-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $108.81 | 2021-2025 | Trintellix |
| Pfizer INC. | $104.94 | 2022-2025 | |
| Sanofi Pasteur INC. | $99.66 | 2021-2023 | |
| Seqirus USA INC | $61.97 | 2022-2025 | Fluad, Flucelvax |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $60.22 | 2021-2025 | Capvaxive, Gardasil 9, Gardasil |
| Cranial Technologies, INC | $51.07 | 2022-2023 | Doc Band |
| Kaleo, INC. | $45.67 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $45.57 | 2023-2024 | Nuedexta |
| Medtronic, INC. | $37.88 | 2023 | Intellis Adaptivestim |
| Genentech USA, INC. | $22.14 | 2021 | |
| Antares Pharma, INC. | $17.35 | 2025 | Xyosted |
| Esperion Therapeutics, INC. | $17.35 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $16.66 | 2025 | Contrave |
| Tolmar, INC. | $15.93 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Strapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.